GNI Group Ltd 3G6
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 12.90
- Day Range
- JPY 13.20–13.20
- 52-Week Range
- —–—
- Bid/Ask
- JPY 0.00 / JPY 0.00
- Market Cap
- JPY 658.41 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 20.48
- Price/Sales
- 3.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 865
- Website
- http://www.gnipharma.com
Comparables
Valuation
|
Metric
|
3G6
|
4563
|
4974
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.48 | — | 66.18 |
Price/Book Value | 3.11 | 0.36 | 1.09 |
Price/Sales | 3.72 | 34.83 | 2.79 |
Price/Cash Flow | 18.37 | — | 22.05 |
Price/Earnings
3G6
4563
4974
Financial Strength
|
Metric
|
3G6
|
4563
|
4974
|
|---|---|---|---|
Quick Ratio | 2.60 | 0.85 | 5.27 |
Current Ratio | 2.97 | 1.63 | 7.45 |
Interest Coverage | 9.30 | — | 52.29 |
Quick Ratio
3G6
4563
4974
Profitability
|
Metric
|
3G6
|
4563
|
4974
|
|---|---|---|---|
Return on Assets (Normalized) | 21.89% | −12.91% | 1.43% |
Return on Equity (Normalized) | 40.90% | −15.67% | 1.60% |
Return on Invested Capital (Normalized) | 37.19% | −15.23% | 1.49% |
Return on Assets
3G6
4563
4974
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Pwpzzpk | Fcbrkc | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zcqtvnfvp | Nplwy | $114.2 Bil | |||
| Moderna Inc
MRNA
| Whczztpq | Dlhf | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Vqpqjkny | Vjdyk | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Jkklsvcy | Jvxm | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jhvqsvr | Zlchgw | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ytbpnkm | Wlrwxm | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Mrsyknvwg | Zpty | $12.8 Bil | |||
| Incyte Corp
INCY
| Wvpjrvcp | Pvsdyt | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Gcxjznytm | Qljjtl | $12.2 Bil |